Immunomodulatory effects following focal ablation of localized prostate cancer with irreversible electroporation (IRE)

Not Applicable

Completed

• Conditions: ocalised Prostate Cancer; Localised Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12622000021774
• Lead Sponsor: St. Vincent's Private Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-12
• Study Completion: 2022-05-29
• Last Update Posted: 30 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

Patients must meet the following inclusion criteria to be eligible to participate in the study
•Male, aged 18 years or over
•Confirmed adenocarcinoma of prostate with organ confined (less than or equal to cT2) disease and Gleason 3 + 4 = 7 or Gleason 4 + 3 = 7 prostate cancer.
•Currently scheduled for either IRE or radical prostatectomy
•No previously diagnosed prostate cancer
•No use of immunosuppressive drugs
•Ability to give written informed consent, participate in and comply with study
•Able to attend blood collection centre at appropriate time.

Exclusion Criteria

Patients who meet any of the following exclusion criteria are not eligible to participate in the study
•Use of immunosuppressive drugs
•Previous diagnosis of prostate cancer
•Inability/ incapacity to provide own consent
•Inability/ incapacity for venous blood collection
•PSA >20ng/ml
•greater than or equal to cT3 on DRE

Study & Design

• Study Type: Observational
• Study Design: Not specified